Rezvilutamide clinical trials
Rezvilutamide is named as an intervention in 13 current clinical trials in our China register. 12 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4). The most-studied condition is Prostate Cancer.
How Rezvilutamide works
All drug targets →- Androgen Receptor antagonist AntagonistTarget: AR androgen receptorChEMBL only
- Prostate cancerPhase 3
- Breast cancerPhase 2
- Progression free survivalPhase 2
- Prostate adenocarcinomaPhase 2
- Salivary duct carcinomaPhase 2
- Salivary gland carcinomaPhase 2
- Fallopian tube cancerPhase 1
- Primary peritoneal carcinomaPhase 1
- Triple-negative breast carcinomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650276, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12798, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Rezvilutamide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rezvilutamide
13 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Rezvilutamide
15 conditionsAll 15 conditions
| Condition (as registered) | Trials |
|---|---|
| Prostate Cancer | 4 |
| Biochemical Recurrence | 2 |
| Locally Advanced Prostate Cancer | 2 |
| Oligometastatic Prostate Cancer | 2 |
| Metastatic Prostate Cancer | 1 |
| Hormone Sensitive Prostate Cancer | 1 |
| Chemotherapy Effect | 1 |
| Salivary Gland Neoplasm Duct | 1 |
| Prostate Cancer (Post Prostatectomy) | 1 |
| Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 1 |
| Prostate Cancer Metastatic Disease | 1 |
| Neoadjuvant Therapy | 1 |
| High Risk Prostate Cancer | 1 |
| Intense Endocrine Therapy | 1 |
| Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 13 | 12 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rezvilutamide trials
How many clinical trials are testing Rezvilutamide?
13 current trials in our China register name Rezvilutamide (also registered as SHR3680) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Rezvilutamide trials recruiting patients?
Yes. 12 of the 13 trials are recruiting: 12 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rezvilutamide clinical trials?
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4), Jiangsu HengRui Medicine Co., Ltd (3), The First Affiliated Hospital with Nanjing Medical University (2) and Peking University First Hospital (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rezvilutamide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rezvilutamide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rezvilutamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.